The Bifurcated Rescheduling Confusion: Why Cannabis and Psychedelics Lawyers Must Stay Alert

April 23, 2026

What the Justice Department did on April 23, 2026 is both progress and a warning. DOJ announced that FDA-approved marijuana products and marijuana products subject to a qualifying state-issued medical license are being placed into Schedule III immediately, while a separate administrative hearing beginning June 29, 2026 will consider the broader question whether marijuana itself should move from Schedule I to Schedule III.¹

That is not full rescheduling. It is a split model. And lawyers should pay attention.

The core problem is not reform. The core problem is bifurcation. Federal law now appears willing to treat the same plant differently depending on the channel through which it moves: approved product, state medical lane, or everything else. That may be politically convenient, but it sits awkwardly with the logic of the Controlled Substances Act, which classifies substances by abuse potential, accepted medical use, and dependence risk—not by whether the government likes the paperwork attached to a particular use case.²

That is why this moment matters. DOJ did not simply finalize the 2024 proposal to move marijuana to Schedule III across the board. Instead, it adopted an interim approach that lowers the schedule for some marijuana-linked categories now while sending the broader question to a June 29 hearing.¹ ² If that framework hardens, lawyers could be left navigating a regime in which the same substance is treated one way in a favored channel and another way everywhere else.

That would not be unprecedented. Federal law already does something similar with GHB and sodium oxybate. DEA materials describe GHB as Schedule I, while FDA-approved sodium oxybate products are treated differently under federal law.³ That proves bifurcation can happen. It does not prove bifurcation makes sense.

And that is where the inconsistency becomes harder to ignore. Cocaine remains a Schedule II substance, and ketamine remains in Schedule III. DEA’s current schedule materials classify the substances that way as substances—not as “approved versions get one schedule, illicit versions become Schedule I because the government dislikes them more.”⁴ Criminal law already handles unlawful possession, diversion, trafficking, and manufacturing. Scheduling is supposed to describe the substance’s legal classification, not serve as a second moral penalty layer.

That distinction matters for both cannabis and psychedelics. If marijuana has accepted medical use sufficient to justify Schedule III treatment, the intellectually coherent move is to reschedule marijuana, not just selected slices of the marijuana market.² The same problem will arise when psychedelic compounds move through FDA pathways. If psilocybin- or MDMA-based products eventually obtain approval, lawyers should be alert to any effort to preserve the fiction that the approved version has accepted medical use while the non-approved version of the same substance somehow still belongs in Schedule I solely to preserve symbolic severity.

None of this means non-medical use becomes legal. It does not. DOJ’s 2024 proposed rule made clear that even if marijuana is moved to Schedule III, federal criminal prohibitions would still apply to unlawful manufacture, distribution, dispensing, and possession, and marijuana-containing drugs would still remain subject to the FDCA.² That point is crucial because it undercuts the usual excuse for split scheduling. The government does not need to keep everything outside a preferred channel in Schedule I in order to keep it illegal.

That is the real takeaway. This is a positive step for cannabis reform. But it is also a warning shot. If Washington gets comfortable with a model that says “medical lane gets the lower schedule, everything else stays at the top,” the result will be exactly what bad compromise usually produces: doctrinal incoherence, selective tolerance, and maximal penalties imposed through an increasingly unprincipled framework. Lawyers in both cannabis and psychedelic practice should be on alert now—not later—because once bifurcation becomes the habit, it becomes the precedent.

Footnotes

¹ See Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-issued License in Schedule III, Strengthening Medical Research While Maintaining Strict Federal Controls, U.S. Dep’t of Just. (Apr. 23, 2026) (justice.gov)

² See Schedules of Controlled Substances: Rescheduling of Marijuana, 89 Fed. Reg. 44597 (May 21, 2024) (federalregister.gov)

³ See Gamma-Hydroxybutyrate (GHB), Drug Enf’t Admin. Drug Fact Sheet; see also Xyrem (Sodium Oxybate) Information, U.S. Food & Drug Admin. (justice.gov)

⁴ See Controlled Substance Schedules, Drug Enf’t Admin. Diversion Control Div.; Controlled Substances—Alphabetical Order, Drug Enf’t Admin. Diversion Control Div. (Apr. 8, 2026) (deadiversion.usdoj.gov)

Harvard-Style References

Drug Enforcement Administration (2026) Controlled substance schedules. Springfield, VA: DEA Diversion Control Division. (deadiversion.usdoj.gov)

Drug Enforcement Administration (2026) Controlled substances—alphabetical order. Springfield, VA: DEA Diversion Control Division, 8 April. (deadiversion.usdoj.gov)

U.S. Department of Justice (2026) Justice Department places FDA-approved marijuana products and products containing marijuana subject to a qualifying state-issued license in Schedule III, strengthening medical research while maintaining strict federal controls. Washington, DC: DOJ Office of Public Affairs, 23 April. (justice.gov)

U.S. Department of Justice (2024) ‘Schedules of controlled substances: Rescheduling of marijuana’, Federal Register, 89 FR 44597, 21 May. (federalregister.gov)